Krukenberg Tumors

2021 ◽  
Author(s):  
Meredith B. Meyer ◽  
Ady Kendler, MD, PhD ◽  
Shaun A. Wahab, MD
Keyword(s):  
Krukenberg Tumors

scholarly journals Treatment strategy and prognostic factors for Krukenberg tumors of gastric origin: report of a 10-year single-center experience from China

Oncotarget ◽  
2017 ◽  
Vol 8 (47) ◽  
pp. 82558-82570 ◽  
Author(s):  
Pengfei Yu ◽  
Ling Huang ◽  
Guoping Cheng ◽  
Litao Yang ◽  
Gaiguo Dai ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Treatment Strategy ◽  
Single Center ◽  
Single Center Experience ◽  
Krukenberg Tumors

Krukenberg tumors of the ovary: Ultrastructural, histochemical, and immunohistochemical studies of 15 cases

Cancer ◽  
1986 ◽  
Vol 57 (4) ◽  
pp. 751-760 ◽  
Author(s):  
Ping Cheung Wong ◽  
Alex Ferenczy ◽  
Lang-Di Fan ◽  
Elliott McCaughey
Keyword(s):  
Krukenberg Tumors ◽  
Immunohistochemical Studies

scholarly journals A young patient in Korea with Krukenberg tumors arising from breast cancer: A case report

2011 ◽  
Vol 54 (10) ◽  
pp. 643 ◽  
Author(s):  
Ha Yan Kwon ◽  
Eun Ji Nam ◽  
Sang Wun Kim ◽  
Young Tae Kim
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Young Patient ◽  
Krukenberg Tumors

Immunoexpression of Inhibin α Subunit, Inhibin/Activin βA Subunit and CD99 in Ovarian Tumors

2000 ◽  
Vol 124 (4) ◽  
pp. 563-569 ◽  
Author(s):  
Yoon-La Choi ◽  
Hy-Sook Kim ◽  
Geunghwan Ahn
Keyword(s):  
Differential Diagnosis ◽  
Granulosa Cell ◽  
Mucinous Carcinoma ◽  
Ovarian Tumors ◽  
Serous Carcinoma ◽  
Α Subunit ◽  
Stromal Tumors ◽  
Epithelial Tumors ◽  
Krukenberg Tumors ◽  
Sex Cord Stromal Tumors

Abstract Objective.—Anti–inhibin α and inhibin/activin βA subunit and anti-CD99 monoclonal antibodies (mAbs) have recently been demonstrated to be able to label ovarian granulosa cells; thus, they may be of value in the diagnosis of granulosa cell tumors. The present study aimed to determine what combination of these mAbs may be useful for the differential diagnosis of sex cord–stromal tumors of ovary. Design.—Immunohistochemical analyses with anti–inhibin α and inhibin/activin βA subunit antibody and anti-CD99 mAb were performed on 42 ovarian tumors, including sex cord–stromal tumors (29), ovarian epithelial cancers (10), and Krukenberg tumors (3). Results.—All sex cord–stromal tumors were positive for inhibin α subunit, and 17 cases (58.6%) of sex cord–stromal tumors were immunoreactive for inhibin/activin βA subunit. Epithelial tumors and Krukenberg tumors were all negative for inhibin/activin βA subunit except mucinous carcinoma, which showed strong cytoplasmic immunoreactivity. All sex cord–stromal tumors except one granulosa cell tumor showed membranous staining for CD99. A case of serous carcinoma and a case of mucinous carcinoma were positive for CD99, and the remaining epithelial tumors and Krukenberg tumor were all negative for CD99. Conclusions.—The results of immunohistochemical analysis, together with literature review, suggest that inhibin α subunit may be a useful diagnostic marker for sex cord–stromal tumor of the ovary. In addition, anti-CD99 antibody may be useful for the differential diagnosis between ovarian tumors. Inhibin/activin βA subunit has a limited usefulness in the differential diagnosis of ovarian tumor because of its wider immunoreactivity for both sex cord–stromal tumors and mucinous carcinomas. The differential diagnosis of sex cord–stromal tumors of the ovary would be better made with a combined use of both anti–inhibin α subunit and anti-CD99 mAbs.

scholarly journals Krukenberg Tumor in Association with Ureteral Stenosis Due to Peritoneal Carcinomatosis from Pulmonary Adenocarcinoma: A Case Report

Medicina ◽  
2020 ◽  
Vol 56 (4) ◽  
pp. 187
Author(s):  
Irina Balescu ◽  
Nona Bejinariu ◽  
Simona Slaniceanu ◽  
Mircea Gongu ◽  
Brandusa Masoud ◽  
...  
Keyword(s):  
Peritoneal Carcinomatosis ◽  
Pulmonary Adenocarcinoma ◽  
Krukenberg Tumor ◽  
Ureteral Stenosis ◽  
Ovarian Metastases ◽  
Pulmonary Lesions ◽  
Krukenberg Tumors ◽  
The Right ◽  
Immunohistochemical Studies ◽  
Rare Situation

Krukenberg tumors from pulmonary adenocarcinoma represent an extremely rare situation; only a few cases have been reported. The aim of this paper is to report an unusual such case in which almost complete dysphagia and ureteral stenosis occurred. The 62-year-old patient was initially investigated for dysphagia and weight loss. Computed tomography showed the presence of a thoracic mass compressing the esophagus in association with a few suspect pulmonary and peritoneal nodules, one of them invading the right ureter. A biopsy was performed laparoscopically on the peritoneal nodules. The right adnexa presented an atypical aspect; right adnexectomy was also found. The histopathological and immunohistochemical studies confirmed that the primitive origin was pulmonary adenocarcinoma. Although both peritoneal carcinomatosis and ovarian metastases from pulmonary adenocarcinoma represent a very uncommon situation, this pathology should not be excluded, especially in cases presenting suspect pulmonary lesions.

scholarly journals Systemic treatment of Krukenberg tumors

2017 ◽  
Vol 30 (4) ◽  
pp. 180-183
Author(s):  
Agnieszka Kolak ◽  
Michal Lozinski ◽  
Slawomir Mandziuk
Keyword(s):  
Colorectal Cancer ◽  
Residual Disease ◽  
Diagnostic Procedures ◽  
Health Condition ◽  
Ovarian Tumors ◽  
Future Research ◽  
Abdominal Girth ◽  
Cancer Symptoms ◽  
Primary Ovarian Cancer ◽  
Krukenberg Tumors

Abstract Of all ovarian tumors with distinct biological features, 10-25% are secondary ovarian tumors. Among the most common cancers that cause ovarian metastasis are breast cancer, colorectal cancer, endometrium, as well as gastric and lateral cancer. Krukenberg tumors remain asymptomatic until the tumor reaches a certain size, as in the case of primary ovarian cancer. Symptoms are non-specific: abdominal pain (42%), postmenopausal bleeding (18%), weight loss (6%) and an increasing abdominal girth (15%). Diagnostic procedures should include physical examination, basic blood and biochemistry tests, radiographic imaging and endoscopy. There are currently no uniform guidelines to be followed in order to treat this cancer. However, the survival rate of selected subgroups of patients may be enhanced by means of cytoreductive surgery (performable among patients with good general health condition), where the metastases are limited only to the ovaries, where the primary tumor is derived from the colorectal cancer, and where there is the absence or minimal residual disease. It is still controversial to use adjuvant chemotherapy following the metastasectomy of Krukenberg tumors. Although this type of treatment seems to provide a survival benefit, there are currently no randomized prospective trials available so as to confirm or deny. Future research should, therefore, be focused on the potentially synergistic effect of surgery and perioperative administration of cytotoxic therapies targeted at high response rates. Studies on new molecularly targeted drugs can also be beneficial.

KRUKENBERG TUMORS

1957 ◽  
Vol 12 (2) ◽  
pp. 283-284
Author(s):  
MELVIN A. RABE
Keyword(s):  
Krukenberg Tumors
Sign in / Sign up

Export Citation Format

Share Document